Last reviewed · How we verify
NCT06157333
Efficacy of Accelerated Repetitive Transcranial Magnetic Stimulation on Patients With Post-stroke Depression
NA trial testing The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) in Post-stroke Depression in 24 participants. Completed in 11 July 2023.
11 July 2023
Quick facts
| Lead sponsor | Ankara City Hospital Bilkent |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 7 February 2022 |
| Primary completion | 11 July 2023 |
| Estimated completion | 11 July 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)
Conditions studied
- Post-stroke Depression — all drugs for Post-stroke Depression →
Sponsor
Ankara City Hospital Bilkent
Who can join
Adults 18 to 75, any sex, with Post-stroke Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The FDA approved repetitive transcranial magnetic stimulation (rTMS) for patients with Major Depressive Disorder (MDD) in 2008. The conventional rTMS protocol that has been used effectively for major depression is 5 days per week for 4-6 weeks. The accelerated rTMS protocol involves conducting more than one session per day. In the treatment of post-stroke depression (PSD); although the effectiveness of conventional rTMS procedure has been shown in many studies, there is limited data on accelerated rTMS protocol in which the number of daily sessions is increased. In this study, we aimed to evaluate the efficacy of accelerated rTMS treatment on depression symptoms in patients diagnosed with PSD and whose depressive symptoms persist despite medical treatment, by comparing it with sham stimulation. Question 1: Is accelerated rTMS an effective and reliable method in the treatment of post-stroke depression? Question 2: Is accelerated rTMS effective on quality of life, functional assessment and motor recovery in patients with post-stroke depression?
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06157333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of The Magstim Rapid2 Plus Magnetic Stimulator (Magstim, Whitland, Dyfed, UK)
Trials testing the same drug.
- NCT06215079 — Investigation of the Efficacy of Transcranial Magnetic Stimulation in Patients Developing Complex Regional Pain Syndrome · NA · unknown
Other recruiting trials for Post-stroke Depression
Currently open trials in the same condition.
- NCT07294274 — Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke · recruiting
- NCT06598670 — Transcranial Direct Current Stimulation on Post Stroke Depression · NA · recruiting
Other Ankara City Hospital Bilkent trials
Trials by the same sponsor.
- NCT07496788 — Investigation of the Role of Internal Jugular Vein Collapsibility Index in Predicting Spinal Anesthesia-Induced Hypotens · not yet recruiting
- NCT07536464 — PEEP Strategies and Mechanical Power in Robotic Surgery · NA · not yet recruiting
- NCT07534553 — Mechanical Power Ventilation in RALP · NA · not yet recruiting
- NCT07501468 — Ventilation Safety in Beach Chair Shoulder Surgery: SafeLM Versus I-gel · NA · not yet recruiting
- NCT07502209 — Suprascapular Nerve PRF in Chronic Shoulder Pain · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06157333 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara City Hospital Bilkent
- Last refreshed: 5 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06157333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing